Firms To Watch: Life sciences and healthcare: PRC firms

Beijing DaHui Lawyers handles M&A and investment funds work for innovative start-ups in the PRC life sciences space. The team is led by Richard Ma, a TMT specialist expanding his work into this sector. Cloud Li is also key.
Commerce & Finance Law Offices is noted for its strong track record in handling large IPOs, M&A and cross-border financings on behalf of medical device companies, pharmaceutical groups, and biotech and medical technology start-ups. The firm has China-wide capability with lawyers based in Beijing, Shanghai and Shenzen.
Guantao Law Firm's life sciences practice is recommended for its abilities to assist with financings and transactional work. The firm also advises on liquidations and restructurings within the sector. Nanjing based Shuangqiang Huang leads the team.
PacGate Law Group's burgeoning life sciences practice offers capability in financing work and IP litigation for pharmaceutical companies and medical technology start-ups. The firm is an innovative boutique in this space, with lawyers including practice head Justin Chen holding biology and biochemistry qualifications.

Life sciences and healthcare: PRC firms in China

Fangda Partners

Fangda Partners offers an extensive life sciences and healthcare focussed team representing an array of medical technology companies and investors, both PRC and multinational. The team is particularly recommended for its expertise in financing and fundraisings. Practice head Josh Shin is expert on regulatory-related issues including R&D, clinical trials, HGRAC regulation and patient centric transformation. Kate Yin is recommended for handling investigations work in the healthcare space, covering anti-bribery, accounting fraud, securities law, conflict of interest, trade secrets and data security. IP expert Fang Qi, antitrust investigations specialist Michael Han and the M&A and foreign investment focussed Diana Li are also central to the team. Henry He, who joined the firm from C-Stone Pharmaceuticals in January 2023, is a further key name.

Practice head(s):

Josh Shin

Other key lawyers:

Kate Yin; Michael Han; Fang Qi; Henry He; Diana Li


‘The staff has a keen awareness and rich experience in regulatory changes and regulatory practices in the pharmaceutical industry, which is trustworthy.’

‘We trust their professional interpretation and advice.’

‘Fangda’s life science and health care lawyer team is very professional and can provide efficient services to clients, including different types of transactions in this field, such as CMO under the background of MAH reform of drug management law and other project legal services.’

‘Josh Shin is an outstanding partner.’

‘Can provide one-stop legal services for pharmaceutical companies and life science and technology companies.’

‘Diana Li has deep insights into the pharmaceutical industry and knows how to provide professional legal services to pharmaceutical clients.’

‘With significant and long-term industry experience in the field of life sciences and healthcare, as well as outstanding achievements in domestic and overseas financing, the team is stable and provides continuous legal support to clients.’

‘One of the very best PRC law firms that can provide full services to its clients.’

Key clients

Eight-Roads Capital

Hengrui Pharmaceuticals

Duality BioScience


Carl Zeiss



Beijing Kexing


Bayer Healthcare


Roche China

Gilead Sciences

Abbott China

WuXi AppTech

Watson Pharmaceuticals

Mindray Medical

APBI Holdings

Danaher Corporate


TPG Growth

Sino Medcare

Roper Technology

Assembly BioScience

Edding Pharm

Everbright Healthcare Fund

C-Stone Pharmaceutical

Hanhui Pharma

Shanghai Kehua Bioengineering


Brooks Automation

EdiGene Beijing Biotechnology

LifeTech Scientific Corporation

Wuxi JW Therapeutics

CBC Group


Primavera Capital

CDBI Capital

CICC Healthcare Fund

CVC Capital

Hillhouse Capital

Highlight Capital

Haeir Healthcare

Johnson & Johnson


Anheart Therapeutics

Smith & Nephew


Visen Pharmaceuticals

Laekna Therapeutics

Smith & Nephew

Vyaire Medical


Vazyme Biotechnology

Zai Lab

CMS (China Medical System)

CDH Fund


MicroPort Group

Cenova Capital

Bristol-Myers Squibb


I-Mab BioPharma

Brii BioScience

Overland Pharmaceuticals

Oncusp Therapeutics

Galixir Technology

Virogin Biotech

Thermo Fisher

Ortho Diagnostics

Eli Lilly


Kintor Pharmaceutical

MediTrust Health

AZ-CICC Healthcare Fund

magAssist Technology

Perkin Elmer

Beijing Naton Technology

Work highlights

  • Represented InnoCare Pharma Limited as the company counsel in its STAR Market listing in Shanghai to raise RMB 2.9 billion, after its IPO on HKEX.
  • Advised MediTrust Health on its Series C+ financing led by HSBC and its entering into strategic agreement with HSBC.
  • Acted as PRC counsel of Abu Dhabi Investment Authority (“ADIA”) as the lead investor in its equity investment in CBPO Holdings Limited (“CBPO”, the offshore holding company of Taibang Biologics), with the total purchase price of US$ 300,000,000.

Global Law Office

Global Law Office‘s healthcare and life sciences team aims to provide a “one-stop” service for clients in the sector, handling M&A, investment and funding, licensing, day-to-day operational matters, IP protection, and compliance advice. The firm assists major MNCs in this capacity – including GSK, Roche and Amgen – as well as PRC state-owned enterprises. The practice is led jointly by Alan Zhou, a specialist in private equity and venture capital funds in the life sciences and medical technology field, and M&A and foreign direct investment specialist Michael Yu. Jerry Liu is also integral, with experience acting for investors as well as directly for biopharmaceutical companies. Licensing and collaboration agreements expert Charlene Huang, healthcare compliance specialist Coco Fan and certified fraud examiner Jacky Li are further key cogs in the team, as is associate Stephanie Wang.

Practice head(s):

Alan Zhou; Michael Yu

Other key lawyers:

Jerry Liu; Coco Fan; Charlene Huang; Jacky Li; Stephanie Wang


‘The team has strong knowledge of life sciences and biomedicine.’

‘The team has global vision and rich overseas and domestic legal knowledge, as well as practical experience.’

Key clients




Johnson & Johnson




Shanghai Pharma


Boehringer Ingelheim Co., Ltd.

CARsgen Therapeutics Holdings Limited

Full-Life Technologies

Jemincare Group Co., Ltd.

Novagenesis Therapeutix Inc.

Viva Star Bioscience Inc.

Morningside Venture

Work highlights

  • Assisted Full-Life Technologies with acquiring Focus-X Therapeutics.
  • Advised MSD, IDG Capital and several other investors on their participation in the Sichuan Kelun Biotech Series B round of financing.
  • Assisted CARsgen Therapeutics in its cooperation with Huadong Medcine on B-cell maturation antigen (BCMA) CAR T therapy, CT-053.

King & Wood Mallesons

Representing a number of high profile pharmaceutical and biotechnology companies, including Boehringer Ingelheim and Roche, King & Wood Mallesons healthcare and life sciences practice is one of the PRC market’s most sought after. The practice is led by Jianwen Huang, who specialises in regulatory compliance advice for pharmaceutical drug, medical device, health food, and cosmetics producers in China. Mark Zhang, who advises on competition law matters in the healthcare and pharma space, is also key, as are investigations specialist Yuanyuan Zhu, the dispute resolution focussed Fan Yang and corporate compliance expert Ting Liu. Associate Lingbi Li, an expert on foreign and outbound investment matters, is a further key name. The firm is recommended for its understanding of the ‘commercial needs of clients‘.

Practice head(s):

Jianwen Huang

Other key lawyers:

Mark Zhang; Ting Liu, Fan Yang; Yuanyuan Zhu; Lingbi Li


‘Mark Zhang’s team of lawyers provides excellent legal services in the medical field. Its legal application is flexible and its risk considerations are comprehensive, but at the same time the lawyers take into account the commercial needs of clients.’

‘The response time is very fast, especially for urgent and independent issues that can require immediate advice.’

‘They understand business needs and give responses in a short period of time.’

Key clients

Boehringer Ingelheim

Roche / Chugai

Shanghai Brighten Optix Vision Technology Co., Ltd.

Roche / Shionogi

Carestream Investment Management (Shanghai) Co., Ltd.

Konica Minolta (Xiamen) Medical Products Co., Ltd.

Yestar (Guangxi) Medical System Co., Ltd.

Huqiu Imaging (Suzhou) Co., Ltd.

Mega Genomics Limited

Novo Nordisk

Idorsia Ltd

Work highlights

Zhong Lun Law Firm

Zhong Lun Law Firm‘s dedicated healthcare and life sciences practice is recommended for its breadth of capability in this space, covering M&A deals, investment funds, compliance advice and litigation, including trade secrets infringement cases. Changyu Fu is recommended for disputes and arbitration work in this field, including antitrust and criminal matters. Jim Qiu, who specialises in compliance advice for multinational clients operating in China, is also key, as is healthcare and medical technology IP expert Helen Cheng. Dongmei Wang and Yongbin Ge are further names to note. Among the more junior partners, medical product liability disputes expert Yuru Zuo and Qi Lan, who brings the experience of formerly having worked at the State Intellectual Property Office, are the standout names, while associate Shuman Zhang is also highly recommended. Clients describe the team as 'customer-focused, responsive, and problem-solving'.

Practice head(s):

Helen Cheng; Changyu Fu; Dongmei Wang; Yongbin Ge; Jim Qiu

Other key lawyers:

Yuru Zuo; Qi Lan; Shuman Zhang


‘The team of lawyers performed well in providing services for our Healthcare investment project. Their professionalism and legal knowledge are profound, and they are comfortable in applying regulations. They are customer-focused, responsive, and problem-solving. Excellent teamwork and smooth communication.’

‘Deep expertise and a great service attitude. Always responds quickly to our needs and provides effective solutions.’

Key clients

Pfizer Investment Co.,Ltd

GlaxoSmithKline (China) R&D Co., Ltd.

Beaufour-IPSEN (Tianjin) Pharmaceutical Co., Ltd.

Shanghai Roche Pharmaceuticals Ltd.

Nestle (China) Ltd.

Fosun Kite Biotechnology Co., Ltd.

PepsiCo Asia R&D Center Ltd.

China National Medicines Corporation Ltd.

Astellas Pharmaceutical(China)Co.,Ltd.

Beijing Novogene Technology Co.

Beijing Xiaomi Mobile Software Co.

Terumo (China) Investment Co.

Asymchem Laboratories(Tianjin)Co.,Ltd.

Nanjing GenScript Biotechnology Co., Ltd.

China National Medicines Corporation Ltd.

Beijing Stemexcel Technical Co.,Ltd.

Shenzhen Smoore Technology Limited

Porton Biologics Ltd.

MSD China Holding Co., Ltd.

United Imaging Healthcare

Zenas BioPharma

Sequoia Capital China

Doma Biopharmaceutical (Suzhou) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

China Mobile Equity Fund

China Mobile Investment Holding Co., Ltd.

Unisplendour Corporation

Guoxin Micro

Whirlpool (China) Co., Ltd

Ansteel Group

T.Y. Lin International Ltd.

Eagle Quest International Ltd.

Capcon Limited

Sichuan Qian Li Beoka Medical Technology Co.,ltd.

Qingdao Magene Intelligent Technology Co., Ltd.

AltoBeam Inc.

Shanghai Enflame Technology Co., Ltd.

Shenzhen Jaguar Microsystems Co., Ltd.

TREX Technologies

Shanghai Yibu Semiconductor Ltd.

Arcomicro Ltd.

Redhill Capital

Jadestone Capital

Work highlights

  • Regularly advising Pfizer Investment on various compliance matters in area of life sciences and healthcare as well as assisting it in enhancing and updating its compliance system.
  • Advised Sequoia Capital China, one of the top venture capital firms, on their CNY 265 million Series A equity investment in BoomRay Pharmaceuticals as the lead investor with other co-investors.
  • Acted as the lead counsel of Chengdu Yunke Pharmaceutical Co., Ltd in defending a dispute lawsuit of technical secret infringement raised by a clinician.

Han Kun Law Offices

Han Kun Law Offices has extensive capability in this space with branches of the team in Beijing, Shanghai, Shenzhen, Haikou and Wuhan. The firm is known for representing major multinational pharmaceutical and medical device companies, assisting with M&A deals and financing matters as well as licensing deals, data protection and intellectual property disputes. The team is led by Yinshi Cao, a venture capital and private equity fund investments specialist with a focus on the life sciences space. Aaron Gu is a standout name in the team, with experience advising on regulatory compliance matters in the areas of biologics and chemical drugs, medical devices and cosmetics. Corporate and commercial lawyer Min Zhu and life sciences M&A specialist Aaron Zhou are also key.

Practice head(s):

Yinshi Gao

Other key lawyers:

Aaron Gu; Aaron Zhou; Min Zhu


‘The team has extensive experience in the biomedical field, especially in legal matters related to drug registration.’

‘Aaron Gu was very responsible in his work, and gave timely replies to our questions. He understood the business and gave advice in a down to earth manner. He is a lawyer I personally like to work with very much.’


Key clients





AbbVie Pharmaceutical


Mayo Clinic


Vivo Ventures


Sinovac Biotech

SinoPharm Capital

Singlera Genomics(鹍远生物)



Hua’s Biomedical

SciClone Pharmaceuticals(赛生药业)


Innovent Biologics, Inc.

Sinocelltech Inc

Wallaby Medical Holding, Inc.

Suzhou Abogen Bioscience Co., Ltd.

Oricell Therapeutics Holdings Limited


NeuShen Therapeutics Inc.


Shanghai Center of Biomedicine Development

Chinese Society for Cell Biology – Chinese Society for Cell Therapy

Ortho Clinical Diagnostics

MYVISION Medical Hong Kong Limited

Shanghai SPH New Asia Pharmaceuticals Co., Ltd.

Hoya Medical

Work highlights

  • Represented Wallaby Medical Holding, Inc. in its acquisition of Phenox GmbH and Femtos GmbH.
  • Advised Linden Capital as its PRC counsel on the acquisition of LifeStyles Healthcare, a sexual health and wellness platform, from sellers including Trustar Capital and Humanwell Healthcare.
  • Advised Oricell Therapeutics on its red-chip restructuring and Series B financing.


JunHe LLP‘s ‘professional and practical‘ Shanghai based team advises life sciences and healthcare sector clients in the areas of M&A, capital markets, private equity/venture capital, intellectual property, compliance and dispute resolution. As well as foreign multinationals, the firm also counts major PRC organisations such as CICC among its clients. The team is jointly led by M&A specialist Xudong Tao, IP consultant Zoe Wang, the licensing and litigation focussed James Zhu and foreign direct investment expert Frank Feng. Min Zhao, who assists life sciences clients with liquidation and restructuring, and financing expert Ning Liu are also key.

Practice head(s):

Xudong Tao; Zoe Wang; James Zhu; Frank Feng

Other key lawyers:

Min Zhao; Ning Liu


‘The team has strong business ability. They are familiar with the capital market business and give professional and practical suggestions and plans in matters such as corporate investment and financing.’

‘They can help companies to solve difficulties in an orderly and efficient manner when dealing with any complicated matter.’

‘Rich experience, familiar with overseas legal affairs, can provide relevant legal advice for companies in China and companies in the United States at the same time, and communicate actively and effectively with clients.’

Key clients

Highlight Capital’s fundraising



Canada Pension Plan Investment Board Private Holdings Inc.

InventisBio Co., Ltd

R&G PharmaStudies Co., Ltd.

Huatai Zijin Investment

Tasly Pharmaceutical Group Co., Ltd.

Lepu Medical Technology (Beijing) Co., Ltd.

HBM Holdings Limited

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

China Life Healthcare Fund

Sonova AG

Sichuan Biokin Pharmaceutical Company

Jefferies LLC

JF Wealth Holdings Ltd.

Ge Medical Systems Trade & Development (Shanghai) Co., Ltd.

GE Healthcare

Hubei Jumpcan Pharmaceutical Co., Ltd.

J.P. Morgan Securities China

Work highlights

  • Assisted InventisBio’s Listing with the SSE STAR Market.
  • Assisted Lepu Medical with its Issuance of GDRs on the SIX Swiss Exchange.
  • Advising R&G PharmaStudies on its IPO on the SZSE ChiNext Market.

AnJie Broad Law Firm

AnJie Broad Law Firm provides a comprehensive offering in this space, handling major patent disputes, licensing and collaboration agreements and financing assistance. Hang Cai is the key name to note on the investor side, advising venture capital and private equity firms. Experienced IP litigator Nick Liu, M&A lawyer Long Gu, anti-monopoly law expert Ying Song and the FDI focussed Sanny Liu are also key. Zongxiu Cai is recommended for IPO related work.

Practice head(s):

Hang Cai; Nick Liu; Long Gu; Samuel Hang; Ying Song; Sanny Liu; Zongxiu Cai

Key clients

GlaxoSmithKline Consumer Healthcare (China) Co., Ltd.

Wyeth Pharmaceutical Co., Ltd.

Sino-American Tianjin SmithKline and French Lab., Ltd.

Suzhou Yiduoyun Health Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Suzhou Shengtuo Semiconductor Technology Co., Ltd.

Shanghai Ebos Biotechnology Co., Ltd.


ACON Biotech (Hangzhou) Co.

Shanghai Healthcare Capital

LH Ventures capital

Fosun Pharma

5Y Capital

Work highlights

  • Assisted Sanhome with a pharmaceutical patent dispute, where the patent was initially invalidated by the State Intellectual Property Office of China and the Beijing Intellectual Property Court, but later validated by the Intellectual Property Division of the Supreme People’s Court.
  • Assisting Fosun Pharma’s drugs incubator platform (Fosun Lead) with its licensing and development collaboration and its several portfolio enterprises’ equity financing deals.
  • Advised LH Venture on its series A investment of RMB 50 million in InnoBM.

FenXun Partners

FenXun Partners is particularly recommended for handling patent infringement and enforcement litigation in the PRC life sciences space. As the joint operation partner of Baker McKenzie FenXun, the firm regularly assists large multinational pharmaceutical corporations on their China operations and advises foreign research and development companies on acquisitions in the PRC market. Practice head Vivian Wu and Hong Zhang are the key names to note.

Practice head(s):

Vivian Wu

Other key lawyers:

Hong Zhang

Key clients

Boston Scientific Corporation

Chugai Pharma

Novartis International AG

Shionogi & Co Ltd

Work highlights

  • Advised Boston Scientific Corporation on the acquisition of 65% in Acotec Scientific Holdings Limited through a voluntary conditional partial cash offer.
  • Advised Chugai Pharma on overall enforcement strategy and represented them in a patent linkage action in China.
  • Represented Novartis/Sandoz in a patent infringement lawsuit involving an offer for sale.

Haiwen & Partners

Haiwen & Partners acts for both PRC biotech companies and large foreign financial services investors, assisting with financing work in the healthcare and life sciences space. Practice head Tina Wu is also highly experienced in clinical research, product development and regulatory compliance matters. Key names on the transactional and investment funds side include Hao Bian and Wenzhen Dai.

Practice head(s):

Tina Wu

Other key lawyers:

Hao Bian; Wenzhen Dai; Rui Feng; Ji Hu; Yingqi Li; Frank Wang; Hanguo Zhang

Key clients

China International Capital Corporation Hong Kong Securities Limited

Morgan Stanley Asia Limited

Warburg Pincus

Beijing Strong Biotechnologies, Inc.


Goldman Sachs

BNP Paribas Securities (Asia) Limited

Ping An Healthcare and Technology Company Limited

Citigroup Global Markets Asia Limited

Clarity Medical Group Holding Limited

BMC Medical Co. Ltd.

Lepuxintai Medical Technology (Shanghai) Co., Ltd.

Hangzhou Calibra Diagnostics Co., Ltd.

Demant A/S



Work highlights

  • Advised Lepu Biopharma Co., Ltd. on issuing shares and listing on the main board of the Hong Kong Stock Exchange.
  • Assisted ByteDance with acquiring 100% equity of Amcare.

Llinks Law Offices

Llinks Law Offices has established a strong IPOs focussed practice, with lawyers also offering FDI, compliance, M&A and commercial law experience. The firm is well recommended for assistance provided to Chinese clients developing innovative medical technologies and introducing these products to the market, and is noted by clients for providing ‘all-round integrated services‘. The key lawyers in the team are cross-border investment specialist David Yu, intellectual property matters expert Xun Yang and the IPOs focussed Wayne Chen.

Other key lawyers:

David Yu; Wayne Chen; Xun Yang


‘The law firm can provide clients with efficient and accurate legal services based on historical project experience and the latest industry trends.’

‘Able to provide clients with investment and compliance consulting, industry research and other all-round integrated services. Their response speed exceeds expectations.’

Key clients

Jiangsu Bioperfectus Technologies Company, Ltd

Zhejiang UE Medical Corp.

Shenzhen Chipscreen Biosciences Co.,Ltd

Shanghai Henlius Biotech, Inc.

ShangHai Allist Pharmaceuticals Inc

Alihealth Technology (China) Co.,Ltd.

Shanghai Fushi Medical Technology Co., Ltd.

Shanghai Cell Therapy Group Co. Ltd.

Ortho-Clinical Diagnostics Trading (China) Co., Ltd.

Shengzhong Hospital Management (Shanghai) Co., Ltd.

Work highlights

Shihui Partners

Shihui Partners advises a range of PRC venture capital firms and medical technology companies on transactional and financing work, including licensing deals and development collaborations. Jing Lu, who is dual qualified in New York and the PRC and has experience in advising multinational pharmaceutical companies operating in China, leads the team jointly with capital markets and private equity specialists Miranda Jiang and Xiaomei Li. Zan Zhu is another key name to note. Clients recommend the firm for its 'very good' service quality and 'strong business logic'.

Practice head(s):

Jing Lu; Miranda Jiang; Xiaomei Li

Other key lawyers:

Zan Zhu


‘Professional, reliable, and strong business logic. Provides critical opinions. The response speed is very fast.’

‘The service quality is very good. Very capable team.’

‘Good at capital market-related businesses in the life sciences and healthcare fields, especially private equity-related legal services in the primary market. The professionalism of the team is outstanding. They have rich experience in project negotiations, and can solve various related problems.’

‘The quality of project delivery is guaranteed.’

Key clients

Suzhou Wedo Venture Capital Partnership (Limited Partnership)

Huimei Medical Management Consulting (Beijing) Co., Ltd.

Beijing Bluepha Microbial Technology Co., Ltd.

Beijing Xinyang Tecnology Co., Ltd.

Genetron Health (Beijing) Co., Ltd.

Zhejiang Haixinzhihui Technology Co., Ltd.

Suzhou Industrial Park Yuan Fu Venture Capital Limited Partner

CCB International

Nanjing Polymer Medical Technology Co., Ltd

Tianjin Horimed Technology Co., Ltd

Beijing Leadinno Medical Valley Co., Ltd.

Guangzhou Reforgene Medicine Co., Ltd.

Work highlights

  • Advised Suzhou CellPro Biotechnology Co., Ltd. on its Series B financing.
  • Advised Guangzhou Reforgene Medicine Co., Ltd. on its Series Pre-B financing.
  • Advised CCB International on its investment into ShangHai Golden Leaf Med Tec Co., Ltd.

Tian Yuan Law Firm

Tian Yuan Law Firm has a strong client base of innovative PRC enterprises, including producers of chronic disease management medication and ophthalmic medical devices. The firm focuses chiefly on financing work for these clients, with strength in capital markets and equity acquisitions. Practice head Juanjuan Song is experienced in transactional matters in the life sciences space including mergers and restructurings. She is supported by equity financing specialist Jiayun Xie and IPO expert Yan Liu.

Practice head(s):

Juanjuan Song

Other key lawyers:

Jiayun Xie; Yan Liu; Xiaohui Zhu

Key clients

Gaoji Medical Group

ClouDr Group Limited

Beautiful Pastoral

Jiangxi Yimai Sunshine Group Co., Ltd.


Ping An Insurance (Group) Co., Ltd. of China

China Cinda Asset Management Co., LTD.

Jinxin Fertility Group Limited

Beijing Changsheng Zhongkang Hospital Management Co., Ltd.

IDG Capital

Work highlights

  • Assisted ClouDr Group Limited with its the Hong Kong capital market listing, joint sponsored by Morgan Stanley Asia Limited and JP Morgan Securities (Far East) Limited are the joint sponsors of this project.
  • Acted for Jinxin Fertility Medical Group Limited (” Jinxin Fertility”) in obtaining 96.5% of equity of Jiu Zhou Hospital and Hewanjia Hospital.

Allbright Law Offices

Allbright Law Offices handles financing and transactional work for an array of PRC pharmaceutical and biotechnology companies. Key names in this extensive team include private equity and M&A expert Congjun Wen and the capital markets focussed Zhengdong Lao and Rui Wang. Associate Tingting Liu is a specialist in the life sciences and healthcare field, with experience in compliance and investigations work in the pharmaceutical industry.

Other key lawyers:

Congjun Wen; Zhengdong Lao; Rui Wang; Tingting Liu

Key clients

Gracell Biotechnologies (Shanghai) Co., Ltd.

Shanghai Smartee Denti-Technology Co.,Ltd.

Innovation Factory (Beijing) Enterprise Management Co., Ltd

Anhui Yiyi Pharmaceutical Co., Ltd

Hangzhou Lanso Medical Disinfectant Co., Ltd

Menarini (China) Investment Co., Ltd

Roche Diagnostic Products (Shanghai) Co., Ltd

Kawin Technology Co.,Ltd

Huaxia Eye Hospital Group Co., Ltd

Blue Sail Medical Co., Ltd

Shandong Kanghua Biomedical Technology Co., Ltd

China Resources Pharmaceutical Holdings Co., Ltd

Jiangyao Group Co., Ltd

Hefei Cubic Pharmaceutical Co., Ltd

Beijing Shurui Robot Co., Ltd

Jiangsu New Element Pharmaceutical Technology Co., Ltd

Zhejiang Jingxin Pharmaceutical Co., Ltd

Zhejiang Jingxin Pharmaceutical Co., Ltd

Work highlights

Dacheng Law Offices

Dacheng Law Offices is noted for its China wide capability, with offices across China’s regions, from Yunnan in the far south to Heilongjiang on the northern borders. The life sciences team regularly assists both start-ups and established PRC life sciences companies with financing work, with associate Shengdi Mao particularly recommended for handling capital markets and private equity investments in this sector. Andy (Xin) Wang is also integral, assisting with compliance and procurement matters in the life sciences space.

Other key lawyers:

Andy(Xin) Wang; Shengdi Mao

Key clients

Zhejiang Doer Biologics Corporation

Suzhou ExCell Biotechnology Co., Ltd.

Mingdu Zhiyun (Zhejiang) Technology Co., Ltd.

Alpha Biopharma Inc.

LYZZ Capital

Work highlights

  • Assisted Doer Biologic with completing an M&A transaction with Huadong Pharmaceutical.
  • Supported the process of Serious B, B+ and B++ financing of ExCell.
  • Assisted with the process of Serious A+ and B financing of Mindo Zhuyun, and started IPO planning.

Jincheng Tongda & Neal

Jincheng Tongda & Neal handles licensing applications, IP litigation and a range of corporate services – including post transactional restructuring advice – to PRC biotech companies and pharmaceutical equipment suppliers. The firm is well recommended for supporting regionally based clients including those from Sichuan, Suzhou and Liaoning, as well as major centres like Shanghai. Key names to note are the venture capital focussed Lingyan Peng and IP litigator Chengchen Gan.

Other key lawyers:

Lingyan Peng; Chengchen Gan

Key clients

Beijing HaoYaoShi Pharmacy Chain Company Limited

Suzhou Qi-Biodesign Biotechnology Co., Ltd.

Shanghai OPM Biosciences Co., Ltd.

Shanghai Medicilon Inc.

Agents of ZHOU and DU

Shanghai Lee Kai Technology Co., Ltd.

Sichuan Santai Pharmaceutical Technology Co., Ltd

Liaoning Chunguang Pharmaceutical Equipment Co., Ltd.

Work highlights

  • Assisted HaoYaoShi Pharmacy Chain with obtaining a favourable trademark ruling in an infringement case brought by Junyi F&T.
  • Assisted Suzhou Qi-Biodesign Biotechnology Co., Ltd. with rendering legal services on matters related to the company’s equity structure and Angel Round financing.

Jingtian & Gongcheng

Jingtian & Gongcheng is recommended for handling acquisitions and equity takeovers in the PRC healthcare and life sciences market, regularly assisting Chinese companies in this capacity. The firm is also well-recommended for overseeing collaborations in this space, including between research and development companies and major hospitals. The team, which is noted for its ability to ‘understand the needs of customers and provide very practical and operable legal opinions‘, is jointly led by the corporate matters and licensing focussed Hanshuo Zhou and IPOs expert Yuanpeng Lang.

Practice head(s):

Yuanpeng Lang; Hanshuo Zhou

Other key lawyers:

Wei Ren


‘The life science and health care team of Jingtian & Gongcheng is excellent and strong. It has brilliant capabilities in serving listed companies, technology-based enterprises and innovative enterprises.’

‘I recommend Attorney Zhou and his team as an excellent group of lawyers in the field of healthcare.’

‘We do appreciate the service levels with JTGC. They showed us a fine definition of team work.’

‘From my experience working with them, they have the consciousness to put themselves in our shoes, which is a very positive attitude.’

‘The team’s capabilities are very comprehensive, showing a high degree of investment in the project they are tasked with and a strong ability to integrate with the customer’s business.’’

‘Lawyer Zhou Hanshuo has a very comprehensive and in-depth understanding of the field of life sciences. He can quickly understand the key points of the client’s business and major risks, and with his many years of work experience in this industry, he can proactively put forward very valuable suggestions.’

‘They have rich experience in this field, and sufficient knowledge and understanding of laws and regulations in this field to provide customers with practical advice.’

‘Zhou Hanshuo and his team are able to understand the needs of customers and provide very practical and operable legal opinions and suggestions.’

Key clients

Thermo Fisher Scientific


Qitan Tech



LYFE Capital

the C.Q. Pharmaceutical Group

Shanghai RNAcure Biopharma Co., Ltd.


China Resources Zizhu Pharmaceutical Co. Ltd.

Beijing Tong Ren Tang Co., Ltd. Yes

Tong Ren Tang Technologies Co., Ltd. Yes

Beijing Tong Ren Tang Chinese Medicine Company Limited

CCB Private Equity Investment Management Co., Ltd.

Pullos Jianfa (Xiamen) Equity Investment Fund Partnership (Limited Partnership)

Work highlights

  • Represented China General Technology (Group) Holding Co Ltd (“Genertec”) in its acquisition of Baoshihua Medical Group from 7 institutional investors including China National Petroleum Corporation.
  • Assisted Conba with transferring 49.84% equity of Jiangxi Zhen Shi Ming Pharmaceutical (“ZSM”) to a group of both domestic and foreign investors.
  • Advised China Isotope & Radiation Corporation on its collaboration project with several domestic hospitals, including Peking Union Medical College Hospital.